ODAC Endorses TRUQAP Combination Therapy Based on Phase III CAPItello-281 Results Showing Improved Progression-Free Survival and Addressing Unmet Need The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has voted in favor of a new treatment approach involving…
Canadian Association of Optometrists Launches “GetEyeWise” Campaign to Promote Vision Health Awareness If reading fine print has become a challenge, it may be time to “GetEyeWise.” That’s the message behind a nationwide public education campaign launched by the Canadian Association…
Cairn Surgical, Inc. Announces Pivotal Trial Success for Breast Cancer Locator System, Demonstrating Improved Surgical Outcomes Cairn Surgical, Inc., a medical technology innovator focused on improving precision in breast cancer surgery, has announced encouraging results from its pivotal clinical trial…
Agendia Presents FLEX Study Data at ASBrS 2026 Showing Consistent MammaPrint + BluePrint Performance Across Diverse Basal-Type Breast Cancer Groups Agendia®, Inc., a recognized leader in precision oncology for breast cancer, has announced the presentation of new findings from its…
RestorixHealth and Industry Leaders Highlight the Legacy, Innovation, and Healing Power of Hyperbaric Medicine In the evolving landscape of modern healthcare, few therapies demonstrate the blend of historical significance and cutting-edge innovation as effectively as hyperbaric oxygen therapy (HBO2). Each…
E-Scopics Secures FDA Clearance for Enhanced Hepatoscope® Platform E-Scopics has announced a major advancement in liver disease diagnostics with the latest U.S. clearance from the U.S. Food and Drug Administration for its upgraded Hepatoscope platform. This milestone reflects the company’s…
Contineum Therapeutics, Inc. Reports Inducement Equity Grants Under Nasdaq Rule 5635(c)(4) Contineum Therapeutics a clinical-stage biopharmaceutical company focused on developing differentiated therapies for neuroscience, inflammation, and immunology (NI&I) indications, has announced the issuance of inducement equity awards to two newly…
Accendra Health to Announce First Quarter 2026 Financial Results on May 11 Accendra Health, has officially announced the date for the release of its financial results for the first quarter of 2026. The Company will publish its earnings report on…
Incyte Secures U.S. Food and Drug Administration Approval for Jakafi XR Incyte has announced a significant milestone with the approval of Jakafi XR™ (ruxolitinib) extended-release tablets by the U.S. Food and Drug Administration (FDA). This approval introduces a once-daily treatment…
Veradermics Prices Upsized Public Offering and Private Placement, Raising Over $400 Million Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative treatments for pattern hair loss, has announced the pricing of an upsized public offering alongside a…